➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Harvard Business School
Medtronic
McKinsey
Merck

Last Updated: April 11, 2021

DrugPatentWatch Database Preview

Eisai Inc Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Eisai Inc
International Patents:691
US Patents:32
Tradenames:12
Ingredients:10
NDAs:16
Drug Master File Entries: 1

Drugs and US Patents for Eisai Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-001 Feb 13, 2015 RX Yes No   Start Trial   Start Trial
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 DISCN Yes No 8,946,207   Start Trial Y   Start Trial
Eisai Inc FYCOMPA perampanel SUSPENSION;ORAL 208277-001 Apr 29, 2016 RX Yes Yes 8,772,497   Start Trial Y   Start Trial
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-002 Feb 13, 2015 RX Yes Yes   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Eisai Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eisai Inc ARICEPT donepezil hydrochloride TABLET;ORAL 020690-002 Nov 25, 1996 6,372,760   Start Trial
Eisai Inc BANZEL rufinamide SUSPENSION;ORAL 201367-001 Mar 3, 2011 7,750,028*PED   Start Trial
Eisai Inc ARICEPT donepezil hydrochloride TABLET;ORAL 020690-002 Nov 25, 1996 4,895,841   Start Trial
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 6,469,182   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for EISAI INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 23 mg ➤ Subscribe 2013-07-09
➤ Subscribe Oral Suspension 40 mg/mL ➤ Subscribe 2014-06-16
➤ Subscribe Extended-release Tablets 20 mg ➤ Subscribe 2016-12-13
➤ Subscribe Tablets 10 mg ➤ Subscribe 2016-06-27
➤ Subscribe Capsules 4 mg and 10 mg ➤ Subscribe 2019-02-13
➤ Subscribe Tablets 100 mg, 200 mg and 400 mg ➤ Subscribe 2012-11-14
➤ Subscribe Tablets 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg ➤ Subscribe 2016-10-24
➤ Subscribe Orally Disintegrating Tablets 5 mg and 10 mg ➤ Subscribe 2010-06-30

Supplementary Protection Certificates for Eisai Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1087960 C01087960/01 Switzerland   Start Trial PRODUCT NAME: ERIBULIN; REGISTRATION NO/DATE: SWISSMEDIC 59489 20110513
1415987 92858 Luxembourg   Start Trial PRODUCT NAME: LENVATINIB, OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES OU UN HYDRATE DE CELUI-CI
1300396 2013C/003 Belgium   Start Trial PRODUCT NAME: FYCOMPA-PERAMPANEL; AUTHORISATION NUMBER AND DATE: EU/1/12/776/001 20120723
1415987 132016000024218 Italy   Start Trial PRODUCT NAME: LENVATINIB O UN SUO SALE ACCETTABILE FARMACEUTICAMENTE O SUO IDRATO(LENVIMA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1002/001-002, 20150601
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Boehringer Ingelheim
Mallinckrodt
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.